Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) research hub

A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

This study is for people with a type of non-muscle-invasive bladder cancer that has come back after treatment. We're testing a new drug, erdafitinib, against standard treatments to see which is better at preventing the cancer from returning.